Clinical-stage Australian biotechnology company Vaxxas will receive $3.2 million from the US Biomedical Advanced Research and ...

Vaxxas, a clinical-stage biotechnology company commercializing a novel high-density microarray patch (HD-MAP) vaccination ...

Vaxxas and CEPI advance US$ 4.8 million programme for needle-free thermostable mRNA vaccines: Cambridge, Massachusetts Friday, January 24, 2025, 14:00 Hrs [IST] Vaxxas, a clinical ...

The University of Queensland's BASE facility – within the Australian Institute for Bioengineering and Nanotechnology (AIBN) – and Brisbane-based biotechnology company Vaxxas have been announced as ...

BioNet, a global leader in vaccine innovation, proudly announces its selection as a Concept Stage winner in the prestigious United States Biomedical Advanced Research and Development Authority (BARDA) ...

ANDERNACH, GERMANY - Newsaktuell - 14 January 2025 - LTS LOHMANN Therapie-Systeme AG ('LTS'), a leading pharmaceutical ...

The award highlights BioNet's novel mRNA influenza vaccine candidate and its unparalleled manufacturing agility—critical for addressing emerging global health threats. The $50 million Patch ...

The Vaxxas HD-MAP is comprised of thousands of microscopic projections molded into a small patch. Each microprojection is coated with a small dose of vaccine in a dried formulation. When applied ...

PopVax awarded $2M for its patch-delivered mRNA influenza vaccine in collaboration with LTS Lohmann as part of BARDA’s Patch Forward Prize.

Vaxxas has announced that the CEPI, has approved the progression of a $7.2 million program to develop heat-stable, ...

The US$2 million (A$3.2 million) prize will help to accelerate the use of Vaxxas' high-density microarray patch (HD-MAP) technology to administer mRNA vaccines manufactured at UQ's BASE facility.

The selection by BARDA recognizes Vaxxas’ significant advancements towards commercializing its proprietary high-density microarray patch (HD-MAP) for vaccine delivery, including completion of ...